Claims for Patent: 11,491,137

Summary for Patent: 11,491,137

Title:	Methods of improving renal function
Abstract:	Provided herein are methods of improving kidney function in a subject in need thereof.
Inventor(s):	Philip Thomas Frohlich, Andrew James KING, Chidambaram Ramachandran, Sarah Beth Noonberg
Assignee:	Chinook Therapeutics Inc
Application Number:	US17/826,843
Patent Claims:	1. A method of improving kidney function in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof; wherein the subject has been previously diagnosed with IgA nephropathy; and wherein the diagnosis of IgA nephropathy comprises a kidney biopsy, detecting anti-glycan antibodies, detecting deposition of IgA-immune complexes in the kidney, or a combination of any of the foregoing. 2. The method of claim 1, wherein the therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, is from about 0.20 mg to about 1.5 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 3. The method of claim 2, wherein the therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, is from about 0.25 mg to about 1.25 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 4. The method of claim 3, wherein the therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, is from about 0.40 mg to about 0.85 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 5. The method of claim 4, wherein the therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, is about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 6. The method of claim 1, wherein the atrasentan is administered as a pharmaceutically acceptable salt. 7. The method of claim 6, wherein the atrasentan is administered as atrasentan hydrochloride or atrasentan mandelate. 8. The method of claim 7, wherein the atrasentan is administered as atrasentan hydrochloride. 9. The method of claim 7, wherein the atrasentan is administered as atrasentan mandelate. 10. The method of claim 1, wherein the atrasentan is administered as the free base. 11. The method of claim 1, wherein the subject is excreting an average of about 0.5 grams or more of protein in the urine per day for at least about 3 months prior to the first administration of atrasentan, or a pharmaceutically acceptable salt thereof. 12. The method of claim 11, wherein the subject is excreting an average of about 0.3 grams to 2.0 grams of protein in the urine per day for at least about 3 months prior to the first administration of atrasentan, or a pharmaceutically acceptable salt thereof. 13. The method of claim 11, wherein the subject is excreting an average of about 0.5 grams to 1.5 grams of protein in the urine per day for at least about 3 months prior to the first administration of atrasentan, or a pharmaceutically acceptable salt thereof. 14. The method of claim 11, wherein the subject is excreting an average of about 0.75 grams to 1.5 grams of protein in the urine per day for at least about 3 months prior to the first administration of atrasentan, or a pharmaceutically acceptable salt thereof. 15. The method of claim 1, wherein the subject has an average eGFR of about 20 to about 90 mL/min/1.73 m2 for at least about 3 months prior to the first administration of atrasentan, or a pharmaceutically acceptable salt thereof. 16. The method of claim 15, wherein the subject has an average eGFR of about 30 to about 90 mL/min/1.73 m2 for at least about 3 months prior to the first administration of atrasentan, or a pharmaceutically acceptable salt thereof. 17. The method of claim 15, wherein the subject has an average eGFR of about 20 to about 60 mL/min/1.73 m2 for at least about 3 months prior to the first administration of atrasentan, or a pharmaceutically acceptable salt thereof. 18. The method of claim 11, wherein the therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, is from about 0.20 mg to about 1.5 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 19. The method of claim 18, wherein the therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, is from about 0.25 mg to about 1.25 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 20. The method of claim 19, wherein the therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, is from about 0.40 mg to about 0.85 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 21. The method of claim 20, wherein the therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, is about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 22. The method of claim 18, wherein the atrasentan is administered as a pharmaceutically acceptable salt. 23. The method of claim 22, wherein the atrasentan is administered as atrasentan hydrochloride or atrasentan mandelate. 24. The method of claim 18, wherein the atrasentan is administered as the free base. 25. The method of claim 15, wherein the therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, is from about 0.20 mg to about 1.5 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 26. The method of claim 25, wherein the therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, is from about 0.25 mg to about 1.25 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 27. The method of claim 26, wherein the therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, is from about 0.40 mg to about 0.85 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 28. The method of claim 27, wherein the therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, is about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 29. The method of claim 25, wherein the atrasentan is administered as a pharmaceutically acceptable salt. 30. The method of claim 29, wherein the atrasentan is administered as atrasentan hydrochloride or atrasentan mandelate.